Burden of Infectious Diseases Compounded by the Emergence of Newer Diseases, Rising Emphasis on Immunization & Increasing Vaccine R&D Efforts to Drive the Global Human Vaccines Market

Burden of infectious diseases compounded by the emergence of newer diseases, favorable governmental policies, increasing initiatives both at the government and private levels for extending immunization worldwide, and rising investments in research and development of new vaccines are poised to drive the global market for Human Vaccines to reach US$42 billion by 2024.

The global market for human vaccines is expected to witness rapid growth, driven by a number of factors, including growing incidence of infectious diseases, favorable governmental policies, increasing initiatives both at the government and private levels for extending immunization worldwide, and increasing investment by companies for research and development of new vaccines. Emergence of newer diseases also constitutes one of the key drivers propelling market growth. Companies are therefore trying to develop new and more effective vaccines against emerging infections, such as dengue, Ebola, and Zika. The market for human vaccines is also driven by their increasing inclusion of pediatric vaccinations in NIPs (National-Immunization-Programs) across several countries worldwide. Public and private partnership initiatives for promotion of prophylactic vaccines usage, especially in emerging countries is increasing, which is also a factor influencing market growth. Increase in interest in vaccine research and the growing share of emerging countries in consumption are promoting market growth in a big way. Furthermore, vaccines currently are manufactured using new and more advanced technologies like cell-based vaccine production or recombinant technology which has been narrowing down the demand-supply gap in the vaccines market.

On antigen basis, human vaccine types include vaccines for hepatitis, meningococcal, HPV, and pneumococcal vaccines among others. Pneumococcal vaccines represent the largest segment of the overall market for vaccines, driven by the rising Prevnar 13 sales. The segment would continue to be dominant for many years to come. However, cancer vaccines are also showing immense promise. The first ever FDA-approved cancer treatment vaccine Provenge® (sipuleucel) is of the first category that is, customized to each patient. The sipuleucel-T vaccine was designed to stimulate immune response to prostatic acid phosphatase or PAP antigen that is typically found on prostate cancer cells. The lack of an approved vaccine for Zika infection represents a significant unmet medical need, given the WHO estimates that over two billion people are at risk of infection with the virus. The National Institute of Allergy and Infectious Disease (NIAID) is developing a Zika vaccine, phase 2 trials of which are currently ongoing. Meanwhile, in July 2018, scientists reported a highly detailed structure of the Zika virus. This would further enable and enhance the vaccine development efforts. The HPV vaccine segment is also likely to benefit from the FDA’s approval of extended age group (27-45 years) for Gardasil 9.

As stated by the new market research report on Human Vaccines, the United States and Europe are the largest regions for vaccines globally, in revenue generation terms. Product differentiation, high vaccination rates, and launch of innovative vaccines characterize the US market for human vaccines. However, Asia-Pacific, including China and India, represents the fastest growing markets for human vaccines worldwide, driven by large population base and relatively high children population. There has also been a surge of new diseases in the region recently. These include SARS (Severe-Acute-Respiratory-Syndrome), chikungunya and avian flu or influenza A among others. Governments in these countries and also multilateral agencies, such as UNICEF and WHO, are making all efforts to improve vaccination coverage, which is anticipated to push vaccines market growth in the overall Asia-Pacific market. Low immunization rate in Asia-Pacific presents huge untapped market potential for several vaccines. Other major growth drivers include growing middle class population, significant unmet medical needs, growing disposable income, increasing funding and government support, and expanding vaccination programs by GAVI and UNICEF.

Major players in the market include ALK – Abelló A/S, Altimmune, Inc., Astellas Pharma Inc., Bavarian Nordic A/S, BiondVax Pharmaceuticals Ltd., Bharat Biotech, GlaxoSmithKline Plc., Hualan Biological Engineering Inc., Janssen Pharmaceuticals Inc., MedImmune, Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma, Pfizer Inc., Sanofi Pasteur SA, Serum Institute of India Pvt. Ltd., Seqirus, SK BioScience, Takeda Pharmaceutical Company Limited, and Zydus Cadila among others.

The research report titled “Human Vaccines – Market Analysis, Trends, and Forecasts” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections in terms of US$ for all major geographic markets, such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia and Rest of Europe) Asia-Pacific (China, India and Rest of Asia-Pacific), Latin America (Brazil and Rest of Latin America) and Rest of World. Product segments analyzed in the report include Pediatric Vaccines and Adult Vaccines.

For enquiries e-mail us at rsd@strategyr.com or info411@strategyr.com.

For cutting edge analyst reviews on top industries

Follow us on Twitter; Connect with us on LinkedIn; Follow us on Medium